6.17  0.17 (2.83%)		10-24 16:00
Open: 6.05 High: 6.295 Volume: 468,820		Pre. Close: 6 Low: 6.045 Market Cap: 146(M)

Short term
Mid term
Targets	6-month :	7.74	1-year :	9.04
Resists	First :	6.63	Second :	7.74
Pivot price	6.11
Supports	First :	6.06	Second :	5.71
MAs	MA(5) :	6.05	MA(20) :	6.09
	MA(100) :	7.12	MA(250) :	8.01
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	30.7	D(3) :	28.7
RSI	RSI(14): 50.2
52-week	High :	13.88	Low :	4.8

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CYBN ] has closed below upper band by 40.6%. Bollinger Bands are 55.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 24 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	6.3 - 6.33	6.33 - 6.35
Low:	5.98 - 6.01	6.01 - 6.04
Close:	6.12 - 6.16	6.16 - 6.21

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

Tue, 21 Oct 2025
Cybin Stock: Optimism Quickly Fades (NYSE:CYBN) - Seeking Alpha

Thu, 16 Oct 2025
Cantor Fitzgerald Keeps Their Buy Rating on Cybin (CYBN) - The Globe and Mail

Mon, 13 Oct 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN - Sahm

Thu, 18 Sep 2025
Cybin Inc. Strengthens U.S. Market Position with New SEC Filing - TipRanks

Thu, 11 Sep 2025
CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm - Business Wire

Tue, 02 Sep 2025
Cybin Inc. (CYBN) Launches Global Phase 3 Trial for Breakthrough Depression Therapy - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	760 (M)
Shares Float	574 (M)
Held by Insiders	6.9 (%)
Held by Institutions	38.3 (%)
Shares Short	14,900 (K)
Shares Short P.Month	12,740 (K)

EPS	-0.16
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.37
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-32.8 %
Return on Equity (ttm)	-49.1 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.12
Qtrly Earnings Growth	0 %
Operating Cash Flow	-85 (M)
Levered Free Cash Flow	-50 (M)

PE Ratio	-41.14
PEG Ratio	0
Price to Book value	16.67
Price to Sales	0
Price to Cash Flow	-54.88

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.